MRNA
HEALTHCAREModerna Inc
$48.79+2.08 (+4.45%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving MRNA Today?
No stock-specific AI insight has been generated for MRNA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$22.28$59.55
$48.79
Fundamentals
Market Cap$19.4B
P/E Ratio—
EPS$-8.14
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-1.4%
Debt / Equity—
Trading
Volume4.4M
Avg Volume (10D)—
Shares Outstanding396.8M
MRNA News
39 articles- [Form 4] Moderna, Inc. Insider Trading ActivityStock Titan·May 8, 2026
- [Form 4] Moderna, Inc. Insider Trading ActivityStock Titan·May 8, 2026
- These Stocks Are Today’s Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and MoreYahoo Finance·May 8, 2026
- MRNA Stock Alert: Moderna Surges on Hantavirus Vaccine HopesBarchart·May 8, 2026
- How Hantavirus Made Moderna a Must-Own Stock AgainYahoo Finance·May 8, 2026
- Cboe Global Markets stock hits all-time high at 346.58 USDInvesting.com·May 8, 2026
- Moderna flags work on hantavirus vaccines before cruise outbreakThe Boston Globe·May 8, 2026
- [144] Moderna, Inc. SEC FilingStock Titan·May 8, 2026
- Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene TherapyGenetic Engineering and Biotechnology News·May 8, 2026
- Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene TherapyGenetic Engineering and Biotechnology News·May 8, 2026
- Moderna Stock Rises On Positive Phase 3 Flu Data: What Investors Need To KnowBenzinga·May 8, 2026
- Moderna Stock Climbs After Hantavirus Vaccine Data ReleaseTokenist·May 8, 2026
- Moderna Flu Breakthrough And Hantavirus Push Reframe Long Term StoryYahoo Finance·May 8, 2026
- Hantavirus: What to Know About the Virus—and Why Moderna Stock RalliedYahoo Finance·May 7, 2026
- Moderna Stock Rallied on Hantavirus Fears. What to Know.Barron's·May 7, 2026
- Moderna stock jumps 10% amid hantavirus outbreak concernsYahoo Finance·May 7, 2026
- NVAX Stock Eyes Breakout Week: Novavax Claims Patients Were ‘Twice As Likely’ To Pick Its COVID Shot Over Moderna AgainStocktwits·May 7, 2026
- Moderna Shareholders OK Directors, Executive Pay Votes and Ernst & Young as 2026 Auditor at AGMMarketbeat·May 7, 2026
- Is Wall Street Bullish or Bearish on Moderna Stock?Barchart·May 6, 2026
- Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010Yahoo Finance·May 6, 2026
- As AI Rewrites Drug Development, the Industry Gathers in Philadelphia to Work Out the RulesYahoo Finance·May 6, 2026
- Novavax Reports First Quarter 2026 Financial Results and Operational HighlightsYahoo Finance·May 6, 2026
- Cancer Treatments Propel Pfizer Sales Growth as Covid Revenue DwindlesThedailyupside·May 6, 2026
- Pfizer Beats Earnings Estimates. The Drugmaker Is Finding Life After Covid.Yahoo Finance·May 5, 2026
- Chicken or the Egg? Why We Need to Rethink Data and Funding in StartupsEntrepreneur·May 5, 2026
- Sector Update: Health Care Stocks Softer in Afternoon TradingYahoo Finance·May 4, 2026
- Moderna Sees Progress Across Cancer Vaccine, Infectious Disease Pipeline, RBC SaysYahoo Finance·May 4, 2026
- Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era247 Wall St·May 4, 2026
- The Zacks Analyst Blog Highlights Moderna, Merck and Vertex PharmaceuticalsYahoo Finance·May 4, 2026
- MRNA Q1 Deep Dive: International Partnerships and Pipeline Progress Offset Litigation HeadwindsYahoo Finance·May 4, 2026
- Moderna (MRNA) Is Down 10.6% After Q1 Loss Widened On Settlement And EU Vaccine Wins – Has The Bull Case Changed?Yahoo Finance·May 3, 2026
- Moderna's Legal Hit Steals Spotlight From Strong SalesBenzinga·May 1, 2026
- Will S&P 500 Open Up Or Down On May 1 After Best Month Since 2020?Benzinga·May 1, 2026
- Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head studyGlobeNewswire Inc.·Apr 18, 2026
- Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directeGlobeNewswire Inc.·Apr 18, 2026
- PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic NephroblastomaGlobeNewswire Inc.·Apr 17, 2026
- Looks Like M&A Week in 3 Different SectorsThe Motley Fool·Apr 8, 2026
- Oil Tumbles, Nasdaq 100 Jumps 3% As Iran Says It's Ready To Halt Hostilities: 10 Stocks MovingBenzinga·Mar 31, 2026
- Moderna Stock is Soaring. Is It Too Late to Buy?The Motley Fool·Mar 25, 2026
All 39 articles loaded
Price Data
Open$47.11
Previous Close$46.71
Day High$49.05
Day Low$46.73
52 Week High$59.55
52 Week Low$22.28
52-Week Range
$22.28$59.55
$48.79
Fundamentals
Market Cap$19.4B
P/E Ratio—
EPS$-8.14
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-1.4%
Debt / Equity—
Trading
Volume4.4M
Avg Volume (10D)—
Shares Outstanding396.8M
About Moderna Inc
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—